J
James E. Dalen
Researcher at University of Arizona
Publications - 300
Citations - 28906
James E. Dalen is an academic researcher from University of Arizona. The author has contributed to research in topics: Pulmonary embolism & Myocardial infarction. The author has an hindex of 73, co-authored 300 publications receiving 28280 citations. Previous affiliations of James E. Dalen include RMIT University & Baylor College of Medicine.
Papers
More filters
Journal ArticleDOI
A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study
Frederick A. Anderson,H. Brownell Wheeler,Robert J. Goldberg,David W. Hosmer,Nilima A. Patwardhan,Borko Jovanovic,Ann Forcier,James E. Dalen +7 more
TL;DR: Extrapolation of the data from this population-based study suggests that there are approximately 170,000 new cases of clinically recognized venous thromboembolism in patients treated in short-stay hospitals in the United States each year, and 99,000 hospitalizations for recurrent disease.
Journal ArticleDOI
Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.
James H. Chesebro,Genell L. Knatterud,Robert Roberts,Jeffrey S. Borer,Lawrence S. Cohen,James E. Dalen,Harold T. Dodge,C K Francis,D. Hillis,P Ludbrook +9 more
TL;DR: In patients with acute myocardial infarction, rt-PA elicited reperfusion in twice as many occluded infarct-related arteries as compared with SK at each of seven serial observations during the first 90 min after onset of treatment.
Journal ArticleDOI
Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range
Jack Hirsh,James E. Dalen,David Anderson,Leon Poller,Henry I. Bussey,Jack Ansell,Daniel Deykin +6 more
TL;DR: The mainstay treatment for atrial fibrillation is Coumadin Aspirin Reinfarction, but the use of aspirin for other reasons is also being considered.
Journal ArticleDOI
Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety
Jack Hirsh,Theodore E. Warkentin,Stephen G. Shaughnessy,Sonia S. Anand,Jonathan L. Halperin,Robert Raschke,Christopher B. Granger,E. Magnus Ohman,James E. Dalen +8 more
TL;DR: This chapter will review the mechanisms of action of heparin and LMWHs, their pharmacokinetics, anticoagulant effects, side effects, and laboratory monitoring, and the results of clinical trials will be discussed.
Journal ArticleDOI
Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects
Carlo Patrono,Barry S. Coller,James E. Dalen,Valentin Fuster,Michael Gent,Laurence A. Harker,Jack Hirsh,Gerald Juergen Roth +7 more
TL;DR: Abbreviations: ACE trial 5 Acetylsalicylic Acid and Carotid Endarterectomy; CAPRIE study 5 Clopidogrel vs Aspirin in Patients at Risk of Ischemic Events; CI 5 confidence interval; COX 5 cyclooxygenase; DVT 5 deep venous thrombosis; EPISTENT trial 5 Evaluation of Platelet IIb/IIIa Inhibitors for Stenting.